Uncommon EGFR mutations in lung adenocarcinomas: Clinical features and response to tyrosine kinase inhibitors

被引：0
|
作者：
Brindel, A. [1 ]
Althakfi, W. [2 ]
Barritault, M. [3 ]
Bringuier, P-P. [3 ]
Watkin, E. [4 ]
Maury, J-M. [5 ]
Girard, N. [6 ]
Brevet, M. [1 ]
机构：
[1] Grp Hosp Est, Pathol, Bron, France
[2] King Saud Univ, Pathol, Riyadh, Saudi Arabia
[3] Grp Hosp Est, Mol Biol, Bron, France
[4] Selas Cypath, Pathol, Villeurbanne, France
[5] Hop Cardiol, Dept Thorac Surg Pulm & Cardiopulm Transplantat, Bron, France
[6] Inst Curie, Pneumol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA60
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
    Brindel, Aurelien
    Althakfi, Wajd
    Barritault, Marc
    Watkin, Emmanuel
    Maury, Jean-Michel
    Bringuier, Pierre-Paul
    Girard, Nicolas
    Brevet, Marie
    JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 4643 - +
  • [2] EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
    Chen, Zhi-Yong
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Su, Jian
    Yang, Xue-Ning
    Chen, Zhi-Hong
    Yang, Jin-Ji
    Zhou, Qing
    Yan, Hong-Hong
    An, She-Juan
    Chen, Hua-Jun
    Jiang, Ben-Yuan
    Mok, Tony S.
    Wu, Yi-Long
    ONCOLOGIST, 2012, 17 (07): : 978 - 985
  • [3] Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors
    Chang, Jung Hyun
    Han, Yeji
    Ryu, Yon Ju
    Lee, Jin Hwa
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [4] Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
    Kobayashi, Susumu
    Canepa, Hannah M.
    Bailey, Alexandra S.
    Nakayama, Sohei
    Yamaguchi, Norihiro
    Goldstein, Michael A.
    Huberman, Mark S.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : 118 - 122
  • [5] EGFR mutations and EGFR tyrosine kinase inhibitors
    Torri, Valter
    Broggini, Massimo
    Garassino, Marina Chiara
    LANCET ONCOLOGY, 2015, 16 (07): : 746 - 748
  • [6] Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
    Suda, Kenichi
    Mitsudomi, Tetsuya
    CELLS, 2021, 10 (07)
  • [7] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    ONCOGENE, 2009, 28 : S24 - S31
  • [8] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    Oncogene, 2009, 28 : S24 - S31
  • [9] Lung cancers with mutations in EGFR exon 18: Molecular characterization and clinical outcomes in response to tyrosine kinase inhibitors.
    Lai, Wei-Chu Victoria
    Ni, Ai
    Arcila, Maria E.
    Huang, James
    Sabari, Joshua K.
    Arbour, Kathryn Cecilia
    Rudin, Charles M.
    Kris, Mark G.
    Riely, Gregory J.
    Yu, Helena Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas
    Zhang, B.
    Wang, S.
    Qian, J.
    Yang, W.
    Qian, F.
    Lu, J.
    Zhang, Y.
    Qiao, R.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S82 - S82
12345